Read Taconic's response to coronavirus (COVID-19), and visit our toolkit for researchers. Learn More


Constitutive Knockout/Random Transgenic

HLA-B7 Constitutive Knockout /Random Transgenic Mouse Model
This model is produced upon order and takes a minimum of 6 weeks to deliver.

CB6F1 Background

  • Model #
  • Genotype
  • Nomenclature
  • 9661-F
    CB6F1-B2mtm1Unc Tg(B2M)55Hpl Tg(HLA-B*0702/H2-Kb)B7.xx
  • 9661-M
    CB6F1-B2mtm1Unc Tg(B2M)55Hpl Tg(HLA-B*0702/H2-Kb)B7.xx
  • Carries a transgene consisting of fragments of the human HLA-B*0702 gene and mouse H2-Kb gene which encodes a chimeric class I molecule consisting of the human HLA-B7 leader, α1 and α2 domains ligated to the murine α3, transmembrane and cytoplasmic H2-Kb domains
  • Expresses the chimeric HLA-B7 class I molecule on the surface of T and B cells
  • Represents the human HLA-B7 supertype
  • Useful for infectious disease research, vaccine development and testing, safety and immunogenicity testing as well as research directed towards oncology and autoimmune disorders
  • Permits identification of epitopes restricted to the HLA-B7 supertype
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

CB6F1 Background


The HLA-B7 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the cDNA clone of the human HLA-B*0702 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains, all under the control of the murine H2-Kb promoter. This transgene was microinjected into CxB6 zygotes. The resultant mice from Founder Line B7.xx were on backcrossed four generations to C57BL/6J. They were then crossed onto murine B2m knockout/human B2m microinjected line from Chella David at Mayo. This crossbred line was backcrossed two additional generations to C57BL/6J and then bred to homozygosity for all three genes. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived. SNP testing showed that the line was not congenic, and so additional backcrosses were initiated. The line was then intracrossed to homozygosity for all three genes. In the production colony, wild type BALB/cAnNTac females are bred to triple homozygous males on the B6 background to produce CB6F1 pups.


HLA-B7 mice are produced upon order. Available for order now.


Black Agouti



Initial Publication:

Alexander J, Oseroff C, Sidney J, Sette A. (2003) Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes. Human Immunology 64:211-223.

Koller BH, Smithies O. (1989) Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination. Proc Natl Acad Sci USA 86:8932-8935.

Krimpenfort P, Rudenko G, Hochstenbach F, Guessow D, Berns A, Ploegh H. (1987) Crosses of two independently derived transgenic mice demonstrate functional complementation of the genes encoding heavy (HLA-B27) and light (beta 2-microglobulin) chains of HLA class I antigens. EMBO J, 1987, 6(6):1673-1676.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.